This trial is active, not recruiting.

Condition head and neck cancer
Treatments cisplatin, fluorouracil, radiation therapy
Phase phase 3
Sponsor National Cancer Centre, Singapore
Start date September 1998
Trial size 200 participants
Trial identifier NCT00003637, CDR0000066722, EU-98047, NMRC-SQNP01


RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy alone is more effective than radiation therapy plus chemotherapy in treating cancer of the nasopharynx.

PURPOSE: This randomized phase III trial is studying how well radiation therapy and chemotherapy works compared to radiation therapy alone in treating patients with previously untreated cancer of the nasopharynx.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Primary purpose treatment

Primary Outcomes

Clinical response
time frame:
Distant metastases
time frame:
Disease-free survival
time frame:
Overall survival
time frame:

Eligibility Criteria

Male or female participants of any age.

DISEASE CHARACTERISTICS: - Histologically confirmed nasopharyngeal cancer that is previously untreated WHO Type III - Stage III/IV (T3-4 Nx M0 or Tx N2-3 M0) confirmed by CT PNS - No evidence of distant metastases detected on chest x-ray, bone scan, and liver ultrasound PATIENT CHARACTERISTICS: Age: - Not specified Performance status: - ECOG 0-1 Life expectancy: - Not specified Hematopoietic: - WBC greater than 3,000/mm^3 - Platelet count greater than 100,000/mm^3 Hepatic: - SAP and SGOT less than 2 times upper limit of normal - Bilirubin less than 1.4 mg/dL Renal: - Creatinine less than 1.6 mg/dL - Creatinine clearance greater than 50 mL/min Other: - No other malignant disease PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified Other - See Disease Characteristics - No concurrent aminoglycoside antibiotics

Additional Information

Official title Standard Radiotherapy Versus Concurrent Chemo-Radiotherapy Followed by Adjuvant Chemotherapy for Locally Advanced (Non-Metastatic) Nasopharyngeal Cancer
Description OBJECTIVES: - Compare the clinical response, distant metastases, disease-free survival, and overall survival in patients with previously untreated, locally advanced, nonmetastatic nasopharyngeal cancer treated with radiotherapy alone vs concurrent chemoradiotherapy followed by adjuvant chemotherapy. OUTLINE: This is a randomized study. Patients are randomized to receive radiotherapy alone (arm I) or concurrent chemoradiotherapy followed by adjuvant chemotherapy (arm II). - Arm I: Patients receive radiotherapy once daily 5 times a week for 7 weeks. - Arm II: Patients receive cisplatin IV over 6-8 hours for 4 consecutive days every 3 weeks for 3 courses. Concurrent radiotherapy is given once daily 5 times a week over the 7 week treatment period. This chemoradiotherapy is followed 3 weeks later by adjuvant chemotherapy. Patients receive cisplatin IV and fluorouracil IV over 6-8 hours for 4 consecutive days every 4 weeks for 3 courses. Patients are followed every 4 months for the first year, every 6 months for the next 2 years, and then annually thereafter until death. PROJECTED ACCRUAL: A minimum of 200 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in December 2013.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).